<div id="readability-page-1"><p>Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday, December 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.18). HC Wainwright has a &#34;Buy&#34; rating and a $10.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2028 earnings at $0.13 EPS.</p><p>Other analysts have also recently issued reports about the stock. UBS Group  set a $10.00 target price on shares of Savara in a research report on Tuesday. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Savara in a research note on Wednesday, October 8th. Oppenheimer  set a $10.00 price objective on Savara in a research report on Tuesday. JMP Securities lifted their target price on Savara from $8.00 to $11.00 and gave the stock a &#34;market outperform&#34; rating in a report on Thursday, October 23rd. Finally, Wells Fargo &amp; Company increased their price target on Savara from $7.00 to $9.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, December 18th. One research analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company. According to MarketBeat.com, Savara presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.13.</p><p><b>Read Our Latest Stock Report on Savara</b></p><h2>Savara Price Performance</h2><p>Savara stock opened at $6.40 on Thursday. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm's fifty day moving average is $5.12 and its 200 day moving average is $3.66. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -12.07 and a beta of 0.23. </p><p>Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). </p><h2>Institutional Investors Weigh In On Savara</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of SVRA. Prudential Financial Inc. bought a new stake in shares of  Savara during the 2nd quarter worth approximately $30,000.  BNP Paribas Financial Markets increased its stake in  Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares during the period.  May Hill Capital LLC bought a new stake in shares of  Savara during the second quarter worth $32,000.  Brevan Howard Capital Management LP bought a new stake in shares of  Savara during the second quarter worth $33,000.  Finally, Russell Investments Group Ltd. boosted its stake in shares of  Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after purchasing an additional 9,463 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About Savara</h2> (Get Free Report)<p>Savara Inc <span>NASDAQ: SVRA<span></span></span> is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.  </p><p>The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Savara</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Savara Right Now?</h2><p>Before you consider Savara, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.</p><p>While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SVRA

<p>HC Wainwright has increased its FY2027 earnings per share (EPS) estimates for Savara Inc. from ($0.18) to ($0.16). The firm maintains a "Buy" rating with a $10.00 price target. Other analysts have mixed ratings, with an average target price of $9.13. Savara's stock opened at $6.40, with a 52-week range of $1.89 to $7.01. The company focuses on therapies for rare respiratory diseases, with its lead candidate under regulatory review.</p>

What is HC Wainwright's Forecast for Savara FY2027 Earnings?